Live News Reader

Some of the articles presented on this website are accessed through RSS feeds from third-party sources that are not necessarily part of the Histiocytosis Association. While we try to select appropriate feeds to prevent objectionable content from being displayed, the presence of any article does not indicate endorsement or recommendation by the Histiocytosis Association.

If you know of a histio-related article that isn't shown here, please send the article to outreach@histio.org.

Erdheim-Chester disease - Google News
This RSS feed URL is deprecated
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news
Friday, April 20, 2018 8:23:22 PM

What the New Medical Podcast DDx Gets Right About Diagnosis - Slate Magazine

Slate Magazine

What the New Medical Podcast DDx Gets Right About Diagnosis
Slate Magazine
The patient would always end up having some far-fetched condition that never made the original list, some collector's item like Erdheim-Chester Disease, which most doctors, let alone hypochondriacs, will never hear of nor encounter. In medicine, we ...


Wednesday, April 18, 2018 1:31:02 PM

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer - FDA.gov

Medscape

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer
FDA.gov
The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose ...
First-Ever FDA Approval for Erdheim-Chester Disease
First Tx for Erdheim-Chester Disease, a Rare Blood Cancer
FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation
 - -

Monday, November 06, 2017 11:39:27 AM

CNS Abnormalities Common in Erdheim-Chester Disease - Neurology Advisor

Neurology Advisor

CNS Abnormalities Common in Erdheim-Chester Disease
Neurology Advisor
Patients with Erdheim-Chester disease (ECD) are at risk for a variety of central nervous system (CNS) abnormalities, and brain and spine magnetic resonance imaging (MRI) may be necessary to determine the extent of disease and its possible prognosis ...


Friday, February 23, 2018 8:36:41 AM

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease - Cancer Network

Cancer Network

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease
Cancer Network
Erdheim–Chester disease originates in the bone marrow and is characterized by the abnormal multiplication of histiocytes, which can invade normal tissue and organs, including the brain, heart, lungs, and others. Each year the disease is estimated to ...


Thursday, November 09, 2017 3:29:33 PM

Elephants can't jump? IDEA's Mike Rea says some Big Pharma players are crushing old beliefs - Endpoints News

Endpoints News

Elephants can't jump? IDEA's Mike Rea says some Big Pharma players are crushing old beliefs
Endpoints News
These additional approvals include: Perjeta for adjuvant, as well as for neoadjuvant, use in HER2-positive breast cancer, Alecensa for 1st line treatment in ALK-positive NSCLC, Zelboraf in Erdheim-Chester disease, Gazyva for untreated advanced ...


Wednesday, March 28, 2018 8:07:45 AM

Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis - Cancer Therapy Advisor

Cancer Therapy Advisor

Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis
Cancer Therapy Advisor
Vemurafenib confers a durable and clinically beneficial effect among patients with BRAF-mutant Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH), according to a study published in JAMA Oncology.1. Although patients with ECD or LCH ...


Thursday, November 30, 2017 1:39:52 PM

Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation - Rare Disease Report

Rare Disease Report

Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation
Rare Disease Report
Mathew Shanley. The U.S. Food and Drug Administration (FDA) has accepted Genentech's supplemental New Drug Application (sNDA) and granted Priority Review for Zelboraf (vemurafenib), a therapy for patients with Erdheim-Chester disease (ECD) with a BRAF ...
FDA Grants Zelboraf Priority Review for Rare Blood Disease


Monday, August 07, 2017 10:29:49 AM

On Rare Disease Day, experts say 'Don't give up' - KING5.com

KING5.com

On Rare Disease Day, experts say 'Don't give up'
KING5.com
She was given chemotherapy she didn't need that reduced her kidney function to 40 percent. Finally, in 2012 a rheumatologist in Everett figured it out: Bonnie had a rare disease - a slow-growing blood cancer that, if left untreated, is life-threatening ...


Wednesday, February 28, 2018 11:12:54 PM

Genes associated with Erdheim-Chester disease also linked to cancer - Science Daily

Genes associated with Erdheim-Chester disease also linked to cancer
Science Daily
"The discovery of new genes associated with ECD provides hope for improving the diagnoses of a disease that affects so many parts of the body. We also hope it will help us identify new treatments," said Juvianee I. Estrada-Veras, M.D., clinical ...


Monday, April 03, 2017 12:40:33 PM

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
| info@histio.org
Privacy | DisclaimerState Fundraising Notices 
Tax ID: 22-2827069 | Contact Us | Site Map
Follow Me on Pinterest   


¿No Habla Inglés? Si usted puede escribirme sus preguntas y preocupaciones a la dirección de correo electrónico: outreach@histio.org. Nosotros podremos responderle tan pronto nos sea possible. Gracias!